Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Gentile

Showing results (241-250 of 313) with videos related to

Pageof 32
Sort By:
Leukemia & Lymphoma|January 5, 2016
Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patientsArtur Jurczyszyn, Magdalena Olszewska-Szopa, Vania Hungria, et al.
Annals of Hematology|May 28, 2024
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experienceGiuseppe Mele, Daniele Derudas, Concetta Conticello, et al.
Hematological Oncology|March 19, 2021
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working GroupGian Matteo Rigolin, Francesco Cavazzini, Alfonso Piciocchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2013
Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical featuresFortunato Morabito, Laura Mosca, Giovanna Cutrona, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple MyelomaLuca Bertamini, Stefania Oliva, Delia Rota-Scalabrini, et al.
Hematological Oncology|January 30, 2024
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohortEnrica Antonia Martino, Francesca Romana Mauro, Gianluigi Reda, et al.
Annals of Hematology|April 12, 2024
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life studySalvatore Leotta, Uros Markovic, Andrea Duminuco, et al.
Non-Coding RNA|November 24, 2025
The <i>Non-Coding RNA</i> Journal Club: Highlights on Recent Papers-14El Cheima Mhamedi, Florent Hubé, Suresh K Alahari, et al.
The Oncologist|December 16, 2018
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell LymphomasMichele Merli, Marco Frigeni, Laurent Alric, et al.
Blood Advances|July 12, 2022
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cellsSerena Matis, Anna Grazia Recchia, Monica Colombo, et al.
Pageof 32

Showing results (241-250 of 313) with videos related to

Sort By:
Pageof 32
Leukemia & Lymphoma|January 5, 2016
Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patientsArtur Jurczyszyn, Magdalena Olszewska-Szopa, Vania Hungria, et al.
Annals of Hematology|May 28, 2024
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experienceGiuseppe Mele, Daniele Derudas, Concetta Conticello, et al.
Hematological Oncology|March 19, 2021
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working GroupGian Matteo Rigolin, Francesco Cavazzini, Alfonso Piciocchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2013
Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical featuresFortunato Morabito, Laura Mosca, Giovanna Cutrona, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple MyelomaLuca Bertamini, Stefania Oliva, Delia Rota-Scalabrini, et al.
Hematological Oncology|January 30, 2024
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohortEnrica Antonia Martino, Francesca Romana Mauro, Gianluigi Reda, et al.
Annals of Hematology|April 12, 2024
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life studySalvatore Leotta, Uros Markovic, Andrea Duminuco, et al.
Non-Coding RNA|November 24, 2025
The <i>Non-Coding RNA</i> Journal Club: Highlights on Recent Papers-14El Cheima Mhamedi, Florent Hubé, Suresh K Alahari, et al.
The Oncologist|December 16, 2018
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell LymphomasMichele Merli, Marco Frigeni, Laurent Alric, et al.
Blood Advances|July 12, 2022
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cellsSerena Matis, Anna Grazia Recchia, Monica Colombo, et al.
Pageof 32